Symic Biomedical Holdings, LLC is developing a novel class of compounds that target the extracellular matrix, and have numerous acute and chronic clinical applications. Symic exploits technology originally discovered at Purdue University that generates synthetic mimics of tissue structural components; the application of these molecules to the site of tissue injury provides the biological signals necessary to promote healthy repair of the damaged or diseased tissue. The potential applications for these molecules are diverse, and include cartilage repair/regeneration in osteoarthritis (OA), as well as multiple applications associated with vascular interventions. OA is one of the indications that will be pursued with the Series A financing, leveraging the ability to utilize a device development paradigm to generate clinical PoC.
Other investors include: DDF (Den Danske Forskningsfond), Mitsui Ventures, and Ally Bridge Group.